• 1
    Patterson DF, Detweiler DK, Hubben K., et al. Spontaneous abnormal cardiac arrhythmias and conduction disturbances in the dog. Am J Vet Res 1961;22:355369.
  • 2
    Guglielmini C., Chetboul V., Pietra M., et al. Influence of left atrial enlargement and body weight on the development of atrial fibrillation: Retrospective study in 205 dogs. Vet J 2000; 160:235241.
  • 3
    Bonagura JD, Ware WA. Atrial fibrillation in the dog: Clinical findings in 81 cases. J Am Anim Hosp Assoc 1986;22:111120.
  • 4
    Falk RH. Atrial fibrillation. N Engl J Med 2001;344:10671078.
  • 5
    Morley J., Marinchak R., Rials SJ, et al. Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 1996;77:38A44A.
  • 6
    Jalife J. Experimental and clinical AF mechanisms: Bridging the divide. J Interv Card Electrophysiol 2003;9:8592.
  • 7
    Veenhuyzen GD, Simpson CS, Abdollah H. Atrial fibrillation. Can Med Assoc J 2004;171:755760.
  • 8
    Haissaguerre M., Jais P., Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659666.
  • 9
    Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol 2003;91:27D32D.
  • 10
    The AFFIRM Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:18251833.
  • 11
    Gronefeld GC, Lilienthal J., Kuck KH, et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Eur Heart J 2003;24:14301436.
  • 12
    Al-Khatib SM, Shaw LK, Lee KL, et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure Am J Cardiol 2004;94:797800.
  • 13
    Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000;356:17891794.
  • 14
    Madrid AH, Escobar C., Rebollo JMG, et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: Results of the irebesartan-amdiodarone trial. Card Electrophysiol Rev 2003;7:243246.
  • 15
    Joglar JA, Kowal RC. Electrical cardioversion of atrial fibrillation. Cardiol Clin 2004;22:101111.
  • 16
    Jais P., Shah DC, Haissaguerre M., et al. Catheter ablation for atrial fibrillation. Annu Rev Med 2000;51:431441.
  • 17
    Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N Engl J Med 2002;346:20622068.
  • 18
    Cox JL, Boineau JP, Schuessler RB, et al. Five-year experience with the maze procedure for atrial fibrillation. Ann Thorac Surg 1993;56:814823.
  • 19
    Ettinger S. Conversion of spontaneous atrial fibrillation in dogs, using direct current synchronized shock. J Am Vet Med Assoc 1968;152:4146.
  • 20
    Calvert CA, Sammarco C., Pickus C. Positive Coombs' test results in two dogs treated with amiodarone. J Am Vet Med Assoc 2000;216:19331936.
  • 21
    Johnson JT. Conversion of atrial fibrillation in two dogs using verapamil and supportive therapy. J Am Anim Hosp Assoc 1984;21:429434.
  • 22
    Pyle RL. Conversion of atrial fibrillation with quinidine sulfate in a dog. J Am Vet Med Assoc 1967;151:582589.
  • 23
    Bonagura JD. Atrial arrhythmias. In: KirkRW, ed. Current Veterinary Therapy X. Philadelphia , PA : WB Saunders Co; 1989: 271278.
  • 24
    Crystal MA, Rush JE. ECG of the Month. J Am Vet Med Assoc 1991;199:4850.
  • 25
    Hogan DF, Sisson DD, McVey AS. ECG of the Month. J Am Vet Med Assoc 1998;213:610611.
  • 26
    Hamer AW, Mandel WJ, Zaher CA, et al. The electrophysiologic basis for the use of amiodarone for treatment of cardiac arrhythmias. Pacing Clin Electrophysiol 1983;6:784794.
  • 27
    Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:20252034.
  • 28
    Deedwania PC, Singh BN, Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 1999;98:25742579.
  • 29
    Vora A., Karnad D., Goyal V., et al. Control of rate versus rhythm in rheumatic atrial fibrillation: A randomized study. Ind Heart J 2004;56:110116.
  • 30
    Kumana CR, Cheung BM, Cheung GT, et al. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br J Clin Pharmacol 2005; 60: 347354.
  • 31
    Weinfeld MS, Drazner MH, Stevenson WG, et al. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 2000;19:638643.
  • 32
    Bicer S., Nakayama T., Hamlin RL. Effects of chronic oral amiodarone on left ventricular function, ECGs, serum chemistries, and exercise tolerance in healthy dogs. J Vet Intern Med 2002;16:247254.
  • 33
    Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management. Am J Cardiol 1997;80:82G89G.
  • 34
    Middlekauff HR, Stevenson WG, Saxon LA, et al. Amiodarone and torsades de pointes in patients with advanced heart disease. Am J Cardiol 1995;76:499502.
  • 35
    Vorperian VR, Havighurst TC, Miller S., et al. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997;30:791798.
  • 36
    Jacobs G., Calvert C., Kraus M. Hepatopathy in 4 dogs treated with amiodarone. J Vet Intern Med 2000;14:9699.
  • 37
    Bicer S., Fuller GA, Wilkie DA, et al. Amiodarone-induced keratopathy in healthy dogs. Vet Ophthalmol 2002;5:3538.
  • 38
    Burns KE, Piliotis E., Garcia BM, et al. Amiodarone pulmonary, neuromuscular and ophthalmological toxicity. Can Respir J 2000;7:193197.
  • 39
    Harris L., McKenna WJ, Rowland E. Side effects and possible contraindications of amiodarone use. Am Heart J 1983;106:916923.
  • 40
    Brien JF, Jimmo S., Brennan FJ, et al. Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. Drug Metab Dispos 1990;18:846851.
  • 41
    Latini R., Connolly SJ, Kates RE. Myocardial disposition of amiodarone in the dog. J Pharmacol Exp Ther 1983;224:603608.
  • 42
    Pollack PT, You YD. Monitoring of hepatic function during amiodarone therapy. Am J Cardiol 2003;91:613616.
  • 43
    Pollack PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004;75:342351.
  • 44
    Lewis JH, Ranard RC, Caruso A., et al. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679685.
  • 45
    Calvert CA, Pickus CW, Jacobs GJ, et al. Signalment, survival, and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy. J Vet Intern Med 1997;11:323326.
  • 46
    Umana E., Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003;114:5155.
  • 47
    Uechi M., Shimizu A., Mizuno M. Heart rate modulation by sympathetic nerves in dogs with heart failure. J Vet Med Sci 2002;64:10231029.
  • 48
    Rossen RM, Alderman EL, Harrison DC. Circulatory response to vasodilator therapy in congestive cardiomyopathy. Br Heart J 1976;38:695700.